sábado, 14 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 15, 2026

BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM

View original at finance.yahoo.com
BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM 4 Reasons Pfizer Could Be a Value Play You Can't Miss BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • BioNTech ended 2025 with cash and marketable securities totaling EUR 17.2 billion, providing substantial resources for its next development phase.

    60% confidence

  • Pumitamig is BioNTech's flagship program, having shown anti-tumor activity across a broad range of cancers and potential as a combination partner with other agents.

    60% confidence

  • BioNTech's COVID-19 vaccine is distributed in more than 180 countries and regions and holds a market share of more than 50% in key markets.

    60% confidence

  • BioNTech's strategy remains focused on maintaining its COVID-19 vaccine business with Pfizer and using proceeds to advance a diversified pipeline, particularly in oncology.

    60% confidence

  • BioNTech has more than 25 ongoing Phase 2 and Phase 3 oncology studies, 17 clinical programs, and a clinical evidence base including more than 4,000 patients.

    60% confidence

  • BioNTech and Pfizer have delivered more than 5 billion COVID-19 vaccine doses worldwide since 2020.

    60% confidence

  • The 2025 fiscal year was a successful one for BioNTech.

    60% confidence

  • BioNTech's goal is to become a multi-product company by 2030.

    60% confidence

  • BioNTech expects several data updates from key late-stage oncology studies in 2026.

    60% confidence

Data points we hold from this source

BioNTech SE · cash17.2 USD
BioNTech SE · clinical programs17 programs
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM — Source | Via News | pt.VIA.NEWS